ClinicalTrials.gg
Not yet recruitingNCT07950111HA380-SHOCKUpdated Nov 20, 2026

HA380 Hemoadsorption Combined With Continuous Renal Replacement Therapy Versus Continuous Renal Replacement Therapy Alone in Septic Shock

An interventional study of HA380 Hemoadsorption Cartridge and Continuous Renal Replacement Therapy in Septic Shock and Acute Kidney Injury, sponsored by The 108 Military Central Hospital. Not yet recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by The 108 Military Central Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether adding an HA380 hemoadsorption cartridge to continuous renal replacement therapy (CRRT) helps adults with septic shock and acute kidney injury requiring CRRT recover from shock better than CRRT alone. Septic shock is a life-threatening condition in which an infection triggers an excessive inflammatory response, causing very low blood pressure and organ failure. The HA380 cartridge is a device placed in the CRRT blood circuit that is designed to remove inflammatory molecules (cytokines) from the blood.

The main question it aims to answer is: Does CRRT combined with the HA380 cartridge result in a lower blood lactate level (a marker of poor oxygen delivery to the body's tissues) at 24 hours than CRRT alone? Researchers will also compare the two groups in terms of the amount of blood-pressure-supporting medicines needed, blood levels of inflammatory cytokines, organ function, time to recovery from shock, need for organ support, length of intensive care unit (ICU) and hospital stay, survival up to 28 days, and side effects.

Participants will:

  • Be randomly assigned to receive either CRRT combined with the HA380 cartridge or CRRT alone, in addition to the same standard septic shock care
  • If assigned to the HA380 group, receive three HA380 cartridges consecutively, each for 6 hours (18 hours in total), followed by CRRT alone as needed
  • Have their vital signs, medicine doses and blood tests recorded before treatment and at set times up to day 7
  • Be followed up for survival and recovery until day 28
Read the detailed description

Background: Septic shock remains a leading cause of death in ICUs. Excessive release of inflammatory cytokines ("cytokine storm") contributes to vasoplegia, tissue hypoperfusion and multiple organ dysfunction. The HA380 cartridge (Jafron Biomedical, China) is a neutral macroporous resin hemoadsorption device that removes middle-molecular-weight substances, including cytokines, and can be used in series with a CRRT circuit. It is licensed for clinical use in Vietnam by the Ministry of Health (Decision No. 266/QD-BYT, 22 January 2025). Available data on HA380 combined with CRRT in septic shock come mainly from retrospective single-center studies, and randomized evidence is lacking. The Surviving Sepsis Campaign 2026 guidelines issue a weak recommendation against the routine use of blood purification therapies, including hemoperfusion, in sepsis and septic shock, reflecting the limited and uncertain evidence. This trial addresses that evidence gap in a selected population with marked hyperinflammation (IL-6 >500 pg/mL), septic shock requiring high-dose vasopressors and acute kidney injury already requiring CRRT, in whom HA380 can be added to an existing extracorporeal circuit. HA380 is used only within this randomized trial, under Ethics Committee approval and written informed consent.

Objectives: (1) to compare the effects of CRRT combined with HA380 hemoadsorption versus CRRT alone on tissue perfusion, hemodynamics, inflammation and organ function in septic shock; (2) to describe clinical outcomes and safety of the two strategies.

Design: Prospective, single-center, open-label, assessor-blinded, randomized controlled trial with two parallel groups (1:1), conducted in the Medical and Toxicological Intensive Care Unit, 108 Military Central Hospital, Hanoi, Vietnam. Planned recruitment: November 2026 to October 2028, with follow-up to November 2028. The study is part of a doctoral (PhD) program of the 108 Institute of Clinical Medical and Pharmaceutical Sciences.

Participants: Adults with septic shock (Sepsis-3) requiring norepinephrine ≥0.4 µg/kg/min (or equivalent), with plasma interleukin-6 (IL-6) >500 pg/mL (Elecsys IL-6, Cobas system) and acute kidney injury with at least one indication for CRRT.

Randomization, allocation concealment and blinding: After written informed consent (from the patient or legally authorized representative), participants are randomized 1:1 by permuted-block randomization with randomly varying block sizes. The sequence is generated in R (blockrand package) by an independent person not involved in recruitment or treatment, and concealed in sequentially numbered, opaque, sealed envelopes (SNOSE). Treating clinicians cannot be blinded. The person scoring SOFA and SOFA-2, the laboratory staff performing cytokine assays and the statistician are blinded to allocation. To limit bias from the open-label design, vasoactive drugs are titrated in both groups by the same written protocol based on invasive arterial pressure (MAP target ≥65 mmHg, or ≥60 mmHg in patients aged ≥65 years; vasopressors are weaned in the following order: epinephrine, norepinephrine, and then vasopressin).

Interventions: Apart from the study intervention, both groups receive the same standard septic shock management according to the Surviving Sepsis Campaign 2026 guidelines and baseline CRRT started as soon as possible after randomization (within 2 hours): continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (each M100 used for a maximum of 24 hours), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, and unfractionated heparin anticoagulation per study protocol (no anticoagulation if platelet count \<50 ×10⁹/L). In the intervention group, the HA380 cartridge is connected in series after the M100 hemofilter, before blood returns to the patient; three HA380 cartridges are used consecutively for 6 hours each (18 hours of hemoadsorption), after which CRRT alone continues as clinically indicated. If a cartridge clots early, it is removed without replacement, CRRT continues, and the next cartridge is connected at the next scheduled time. Full adherence is defined as use of all three cartridges per protocol with a total hemoadsorption time of at least 16 hours. To limit antibiotic underdosing, loading doses are given before HA380 connection when possible, vancomycin and aminoglycoside levels are monitored in both groups when available, and all antibiotics given in the first 24 hours are recorded.

Time points: R = randomization (time-to-event outcomes are counted from R). T0 = immediately before the first CRRT session (≤2 hours after R). Hemodynamics, vasoactive doses (summarized as VIS and norepinephrine equivalent dose, NEE) and arterial blood gases including lactate (RAPIDPoint 500 analyzer in the ICU, same device for all measurements) are recorded at T0 and at 6, 12, 18, 24, 48 and 72 hours after CRRT initiation. Plasma IL-1β, IL-6, IL-8, IL-10 and TNF-α are measured at T0 and 24 hours (Luminex 200, ProcartaPlex multiplex immunoassay, Vietnam Military Medical University). Hematology, liver and renal function, coagulation, CRP, procalcitonin, ferritin, LDH, SOFA and SOFA-2 scores and the number of organ failures (Knaus criteria) are assessed at T0, day 3 and day 7. APACHE II, SAPS II and mNUTRIC are recorded at baseline. Clinical outcomes are followed to day 28 (D28).

Sample size: Based on An et al. (2025), the mean reduction in lactate after 24 hours of treatment was 1.61 versus 1.04 mmol/L (difference 0.57 mmol/L; pooled SD of 24-hour lactate 0.81 mmol/L; standardized effect size d ≈ 0.70). With two-sided α = 0.05 and 80% power, 32 participants per group are required; inflated by approximately 9% for attrition, 35 per group (70 in total) will be enrolled.

Statistical analysis: The statistical analysis plan is finalized before database lock and before unblinding of the statistician. The primary analysis is intention-to-treat (all randomized participants analyzed as allocated). The primary outcome (arterial lactate at 24 hours) is analyzed by ANCOVA with treatment group and baseline lactate, reporting the adjusted mean difference with 95% CI; participants who die before 24 hours are assigned the highest lactate value observed in the whole sample. Pre-specified sensitivity analyses: (1) log-transformed lactate; (2) additional adjustment for baseline log IL-6, SOFA and epinephrine dose; (3) survivors to 24 hours only; (4) hierarchical rank test (death before 24 hours ranked worst, survivors ranked by lactate); (5) per-protocol population. Repeated secondary measures are analyzed with linear mixed models adjusted for baseline; time to shock resolution with a Fine-Gray competing-risk model (death as competing event); mortality and dialysis dependence with risk ratios, risk differences, Kaplan-Meier, log-rank and Cox models; free-day outcomes with Mann-Whitney U and Hodges-Lehmann estimates; Holm correction across the five cytokines. Pre-specified subgroup: baseline IL-6 below/above the sample median (interaction test). Baseline IL-6 used for the subgroup analysis and sensitivity analysis (2) is the value measured by Elecsys IL-6 at screening (the same assay used for eligibility). No randomized participant is excluded from the primary (intention-to-treat) analysis.

Safety: Adverse events are defined using pre-specified study criteria and graded with CTCAE version 6.0; for abnormalities already present at baseline (e.g., thrombocytopenia, electrolyte disturbances), only treatment-emergent events are counted: a new event of grade ≥1 after T0 in a participant with grade 0 at T0, or worsening by at least one grade from T0. Monitoring windows: hypotension within 30 minutes after CRRT connection and after each HA380 cartridge change (6, 12 and 18 hours); bleeding, thrombocytopenia and hemolysis up to day 7; electrolyte disturbances until the end of CRRT or day 7, whichever comes first; hypothermia by hourly core temperature during CRRT (lowest value recorded every 6 hours in the first 24 hours, then daily) until the end of CRRT or day 7, whichever comes first; anaphylaxis within 72 hours; catheter occlusion, catheter-site infection and catheter-related venous thrombosis daily up to day 14. Extracorporeal circuit incidents (hemofilter membrane rupture, hemofilter clotting, early HA380 clotting, technical machine stoppage) are classified as device deficiencies, defined by objective machine-alarm and observation criteria, and recorded in real time with the machine alarm log until the end of CRRT or 72 hours after CRRT initiation, whichever comes first. Serious adverse events are reported to the Ethics Committee according to national regulations.

Ethics, funding and conflicts of interest: The protocol was approved by the Ethics Committee in Biomedical Research, 108 Military Central Hospital (Certificate No. 7197/GCN-BV, 11 September 2026). HA380 cartridges and cytokine assays are funded by Thanh Phuong Co., Ltd., the Vietnamese distributor of HA380 (donation letter No. 0805/CV-TPC, 8 May 2026). The company has no role in study design, data collection, data analysis, interpretation of results, manuscript preparation or the decision to publish. Participants incur no additional costs.

02

Conditions studied

  • Septic Shock
  • Acute Kidney Injury

Keywords

  • hemoadsorption; hemoperfusion
  • HA380
  • cytokine adsorption
  • continuous renal replacement therapy
  • CVVHDF
  • interleukin-6
  • lactate
  • vasoactive-inotropic score
  • sepsis
03

In context

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 70 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

The 108 Military Central Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Septic shock according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, 2016)
  • Norepinephrine ≥0.4 µg/kg/min, or an equivalent vasopressor dose, required to maintain the target mean arterial pressure
  • Plasma interleukin-6 (IL-6) concentration >500 pg/mL (Elecsys IL-6, Cobas system)
  • Acute kidney injury with at least one indication for continuous renal replacement therapy: serum potassium ≥6.5 mmol/L; pH \<7.2 not due to pure respiratory acidosis; oliguria \<0.3 mL/kg/h for ≥24 hours or anuria for ≥12 hours; fluid overload unresponsive to diuretics, or pulmonary edema; or uremic syndrome
  • Randomization within 24 hours of septic shock onset
  • Written obtained from the patient or the legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • currently treated with chemotherapy or radiotherapy, \<1 ×10⁹/L, therapy after organ transplantation, or AIDS
  • Chronic kidney disease on maintenance dialysis, C cirrhosis, or class IV heart failure
  • Active bleeding, or count \<20 ×10⁹/L to platelet transfusion
  • Allergy to heparin or history of heparin-induced thrombocytopenia
  • Concomitant hemorrhagic shock or anaphylactic shock
  • Expected death within 24 hours, or a do-not-resuscitate order or a family decision to withdraw life-sustaining treatment
  • Cardiac arrest during the current illness before randomization
  • Continuous renal replacement therapy or any hemoadsorption already received during the current hospital admission before randomization
  • Patient or legally authorized representative declines participation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    CRRT + HA380 Hemoadsorption

    Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) plus three consecutive HA380 cartridges, 6 hours each (18 hours in total), connected in series after the M100 hemofilter; CRRT alone continues afterwards as clinically indicated. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines.

    Device: HA380 Hemoadsorption Cartridge · Procedure: Continuous Renal Replacement Therapy

  • Active comparator
    CRRT Alone

    Baseline CRRT (CVVHDF, Prismaflex, M100 hemofilter) without hemoadsorption. Standard septic shock care per the Surviving Sepsis Campaign 2026 guidelines.

    Procedure: Continuous Renal Replacement Therapy

Interventions

  • DeviceHA380 Hemoadsorption Cartridge

    Single-use neutral macroporous resin hemoadsorption cartridge (Jafron Biomedical), primed with heparinized saline according to the manufacturer's instructions and connected in series after the M100 hemofilter, before blood returns to the patient. Three cartridges are used consecutively, each for 6 hours (total 18 hours), starting with the first CRRT session

    Also known as: HA380, Jafron HA380 hemoperfusion cartridge

  • ProcedureContinuous Renal Replacement Therapy

    Continuous venovenous hemodiafiltration (CVVHDF) on the Prismaflex system with an M100 hemofilter (maximum 24 hours per filter), blood flow 150-200 mL/min, effluent dose 25-30 mL/kg/h, lactate-free bicarbonate-buffered solutions, unfractionated heparin anticoagulation per protocol (no anticoagulation if platelet count \<50 ×10⁹/L); started within 2 hours of randomization.

    Also known as: CRRT, CVVHDF

06

What researchers measure

Primary outcomes

  1. Arterial Blood Lactate Concentration at 24 Hours

    Arterial blood lactate (mmol/L) measured by blood gas analyzer 24 hours after initiation of CRRT, compared between groups by analysis of covariance (ANCOVA) adjusted for baseline lactate. Participants who die before 24 hours are assigned the highest lactate value observed in the study sample.

    Time frame: Baseline and 24 hours after initiation of CRRT

Secondary outcomes

  1. Vasoactive-Inotropic Score (VIS)

    VIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 100 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10,000 × vasopressin (U/kg/min), according to Gaies et al. (Pediatr Crit Care Med 2010). Higher scores indicate greater vasoactive and inotropic support. Unit: points (dimensionless score).

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  2. Norepinephrine Equivalent Dose (NEE)

    Total vasopressor dose expressed as norepinephrine equivalents (µg/kg/min), calculated as: NEE = norepinephrine (µg/kg/min) + epinephrine (µg/kg/min) + dopamine (µg/kg/min)/100 + phenylephrine (µg/kg/min)/10 + 2.5 × vasopressin (U/min), adapted from Kotani et al. (Crit Care 2023;27:29) and restricted to the vasopressors permitted in the study protocol. Norepinephrine doses are expressed as norepinephrine base; weight-based vasopressin doses are converted to U/min using the participant's body weight. Inotropes (dobutamine, milrinone) are not included. Higher values indicate greater vasopressor requirement.

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  3. Mean Arterial Pressure

    Mean arterial pressure (mmHg) measured by invasive arterial monitoring.

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  4. Heart Rate

    Heart rate (beats per minute).

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  5. Arterial Blood Lactate Concentration Over Time

    Serial arterial blood lactate concentration (mmol/L) measured by blood gas analyzer at each time point. Lactate trajectories are compared between groups using a linear mixed-effects model for repeated measures adjusted for baseline lactate.

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  6. Lactate Clearance

    Lactate clearance (%) calculated at each time point as (baseline arterial lactate - arterial lactate at the time point) / baseline arterial lactate × 100. Positive values indicate a decrease in lactate from baseline; negative values indicate an increase.

    Time frame: 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  7. Epinephrine Dose

    Epinephrine infusion dose (µg/kg/min)

    Time frame: Baseline and 6, 12, 18, 24, 48 and 72 hours after initiation of CRRT

  8. Number of Participants Receiving Epinephrine in the First 24 Hours

    Number of participants who receive an epinephrine infusion at any time during the first 24 hours of CRRT.

    Time frame: From initiation of CRRT to 24 hours

  9. Duration of Epinephrine Infusion in the First 24 Hours

    Total duration (hours) of epinephrine infusion during the first 24 hours of CRRT.

    Time frame: From initiation of CRRT to 24 hours

  10. Number of Participants With Early Shock Reversal

    Early shock reversal defined as mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) together with a decrease in arterial lactate of more than 20% from baseline.

    Time frame: 6, 12, 18, 24 and 48 hours after initiation of CRRT

  11. Percentage Reduction in Plasma Interleukin-6 (IL-6)

    Percentage reduction in plasma IL-6 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

    Time frame: Baseline and 24 hours after initiation of CRRT

  12. Percentage Reduction in Plasma Interleukin-1 Beta (IL-1β)

    Percentage reduction in plasma IL-1β concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

    Time frame: Baseline and 24 hours after initiation of CRRT

  13. Percentage Reduction in Plasma Interleukin-8 (IL-8)

    Percentage reduction in plasma IL-8 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

    Time frame: Baseline and 24 hours after initiation of CRRT

  14. Percentage Reduction in Plasma Interleukin-10 (IL-10)

    Percentage reduction in plasma IL-10 concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

    Time frame: Baseline and 24 hours after initiation of CRRT

  15. Percentage Reduction in Plasma Tumor Necrosis Factor Alpha (TNF-α)

    Percentage reduction in plasma TNF-α concentration measured by multiplex immunoassay (Luminex): (baseline - 24-hour value) / baseline × 100. Unit: %.

    Time frame: Baseline and 24 hours after initiation of CRRT

  16. Sequential Organ Failure Assessment (SOFA) Score

    SOFA score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation.

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  17. SOFA-2 Score

    SOFA-2 score (range 0-24; higher scores indicate more severe organ dysfunction), calculated by an assessor blinded to group allocation.

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  18. Number of Failing Organ Systems

    Number of failing organ systems (cardiovascular, respiratory, renal, hematological, neurological, hepatic) according to Knaus criteria. Range 0-6.

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  19. Creatinine

    Blood creatinine concentration (µmol/L).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  20. Total Bilirubin

    Blood total bilirubin concentration (µmol/L).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  21. Platelet Count

    Platelet count (×10⁹/L).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  22. International Normalized Ratio (INR)

    Prothrombin time expressed as INR.

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  23. C-Reactive Protein

    Blood C-reactive protein concentration (mg/L).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  24. Procalcitonin

    Blood procalcitonin concentration (ng/mL).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  25. Ferritin

    Blood ferritin concentration (ng/mL).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  26. Lactate Dehydrogenase (LDH)

    Blood LDH activity (U/L).

    Time frame: Baseline, day 3 and day 7 after initiation of CRRT

  27. Time to Shock Resolution

    Time (hours) from randomization to discontinuation of the last vasopressor, with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without vasopressors. Death before shock resolution is treated as a competing event.

    Time frame: From randomization to day 28

  28. Number of Participants With Shock Resolution

    Shock resolution defined as complete discontinuation of vasopressors with mean arterial pressure ≥65 mmHg (≥60 mmHg in patients aged ≥65 years) maintained for at least 24 hours without reintroduction.

    Time frame: From randomization to day 28

  29. Number of Participants With Recurrent Shock

    Recurrent shock defined as reintroduction of vasopressors after shock resolution.

    Time frame: From randomization to day 28

  30. Vasopressor-Free Days

    Number of days alive and free of vasopressors within 28 days after randomization; participants who die before day 28 are assigned 0 days.

    Time frame: From randomization to day 28

  31. Ventilator-Free Days

    Number of days alive and free of invasive mechanical ventilation within 28 days after randomization; participants who die before day 28 are assigned 0 days.

    Time frame: From randomization to day 28

  32. Renal Replacement Therapy-Free Days

    Number of days alive and free of any renal replacement therapy within 28 days after randomization; participants who die before day 28 are assigned 0 days.

    Time frame: From randomization to day 28

  33. ICU-Free Days

    Number of days alive and out of the ICU within 28 days after randomization; participants who die before day 28 are assigned 0 days.

    Time frame: From randomization to day 28

  34. Number of Participants Dependent on Renal Replacement Therapy

    Dialysis dependence defined as still requiring any form of renal replacement therapy on the day of assessment.

    Time frame: Day 7 and day 28 after randomization

  35. Duration of Invasive Mechanical Ventilation

    Number of days on invasive mechanical ventilation.

    Time frame: From randomization to ICU discharge, assessed up to 28 days

  36. Duration of CRRT

    Number of days on continuous renal replacement therapy.

    Time frame: From initiation of CRRT to ICU discharge, assessed up to 28 days

  37. Number of M100 Hemofilters Used

    Total number of M100 hemofilters used during the ICU stay.

    Time frame: From initiation of CRRT to ICU discharge, assessed up to 28 days

  38. Lifespan of the First M100 Hemofilter

    Time (hours) from start of the first M100 hemofilter to its replacement (maximum 24 hours per protocol).

    Time frame: From initiation of CRRT to 24 hours

  39. ICU Length of Stay

    Number of days from ICU admission to ICU discharge.

    Time frame: From ICU admission to ICU discharge, assessed up to 28 days

  40. Hospital Length of Stay

    Number of days from hospital admission to hospital discharge.

    Time frame: From hospital admission to hospital discharge, assessed up to 28 days

  41. ICU Mortality

    Number of participants who die from any cause during the ICU stay.

    Time frame: From randomization to ICU discharge, assessed up to 28 days

  42. In-Hospital Mortality

    Number of participants who die from any cause during the hospital stay. Participants discharged in critical condition at the family's request are followed up by telephone.

    Time frame: From randomization to hospital discharge, assessed up to 28 days

  43. 7-Day All-Cause Mortality

    Number of participants who die from any cause within 7 days after randomization.

    Time frame: From randomization to day 7

  44. 28-Day All-Cause Mortality

    Number of participants who die from any cause within 28 days after randomization.

    Time frame: From randomization to day 28

  45. Number of Participants With Hypotension at CRRT Initiation or HA380 Cartridge Change

    Hypotension defined as a decrease in mean arterial pressure (invasive monitoring) of more than 20% from the pre-connection value, or to \<65 mmHg (\<60 mmHg in patients aged ≥65 years), requiring an increase in vasopressor dose, within 30 minutes after connection of the CRRT circuit or after each HA380 cartridge change.

    Time frame: Within 30 minutes after CRRT initiation and after cartridge changes at 6, 12 and 18 hours

  46. Number of Participants With Bleeding Events

    Treatment-emergent bleeding (catheter site, upper gastrointestinal or intracranial), identified by daily clinical monitoring and confirmed by investigations when clinically indicated, graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT to day 7

  47. Number of Participants With Thrombocytopenia

    Treatment-emergent thrombocytopenia defined as a platelet count decrease of ≥50% from baseline, severity graded by CTCAE version 6.0 according to the lowest platelet count. Platelet counts are obtained at baseline, day 3 and day 7, and whenever clinically indicated.

    Time frame: From initiation of CRRT to day 7

  48. Number of Participants With Hemolysis

    Hemolysis defined as a hemoglobin decrease of ≥20 g/L with laboratory evidence of hemolysis (elevated LDH, decreased haptoglobin, and/or schistocytes on peripheral smear), graded by CTCAE version 6.0. Assessed by laboratory tests at baseline, day 3 and day 7, and whenever hemolysis is clinically suspected.

    Time frame: From initiation of CRRT to day 7

  49. Number of Participants With Electrolyte Disturbances

    Treatment-emergent electrolyte disturbance defined as potassium \<3.0 mmol/L, phosphate \<0.6 mmol/L, ionized calcium \<0.9 mmol/L or magnesium \<0.5 mmol/L, graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT until end of CRRT or day 7, whichever comes first

  50. Number of Participants With Hypothermia

    Core temperature \<35°C during CRRT, based on hourly core temperature monitoring (lowest value recorded every 6 hours in the first 24 hours, then daily), graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT until end of CRRT or day 7, whichever comes first

  51. Number of Participants With Anaphylaxis

    Anaphylaxis according to the Vietnamese Ministry of Health diagnostic criteria, graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT to 72 hours

  52. Number of Participants With Catheter Occlusion

    Dialysis catheter occlusion by clot requiring interruption of CRRT and catheter replacement.

    Time frame: From initiation of CRRT to day 14

  53. Number of Participants With Catheter-Site Infection

    Swelling, erythema, discharge or pus within 2 cm of the dialysis catheter insertion site, graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT to day 14

  54. Number of Participants With Catheter-Related Venous Thrombosis

    Venous thrombosis related to the dialysis catheter, confirmed by ultrasound, graded by CTCAE version 6.0.

    Time frame: From initiation of CRRT to day 14

  55. Number of Participants With Extracorporeal Circuit Incidents

    Number of participants with at least one device deficiency (ISO 14155:2026): hemofilter membrane rupture (blood leak alarm with pink/red effluent); M100 hemofilter clotting requiring unplanned circuit change (TMP \>300 mmHg or unresolved clotting alarm, visible clot, or blood pump stopped by clot); early HA380 clotting requiring removal before 6 hours; or unplanned technical stoppage of the blood pump for ≥15 minutes. Each stoppage is attributed to one primary cause. The number of events per participant is also reported.

    Time frame: From initiation of CRRT until end of CRRT or 72 hours, whichever comes first

07

Study locations

1 site
08

References and documents

Publications

  • Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, Charpie JR, Hirsch JC. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010 Mar;11(2):234-8. doi: 10.1097/PCC.0b013e3181b806fc. PubMed 19794327 ↗
  • Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. PubMed 26903338 ↗
  • Kotani Y, Di Gioia A, Landoni G, Belletti A, Khanna AK. An updated "norepinephrine equivalent" score in intensive care as a marker of shock severity. Crit Care. 2023 Jan 20;27(1):29. doi: 10.1186/s13054-023-04322-y. PubMed 36670410 ↗
  • An Y, Guo Y, Zhou W, He Q, Li Z, Sui X, Yi X, Yi H. HA380 Hemoperfusion Combined with Continuous Veno-Venous Hemodiafiltration for the Treatment of Septic Shock. Bioengineering (Basel). 2025 Apr 9;12(4):400. doi: 10.3390/bioengineering12040400. PubMed 40281760 ↗
  • Ranzani OT, Singer M, Salluh JIF, Shankar-Hari M, Pilcher D, Berger-Estilita J, Coopersmith CM, Juffermans NP, Laffey J, Reinikainen M, Neto AS, Tavares M, Timsit JF, Arias Lopez MDP, Arulkumaran N, Aryal D, Azoulay E, Celi LA, Chaudhuri D, De Lange D, De Waele J, Dos Santos CC, Du B, Einav S, Engelbrecht T, Fazla F, Ferrer R, Finazzi S, Fujii T, Gershengorn HB, Greene JD, Haniffa R, Hao S, Hasan MS, Hollenberg S, Ippolito M, Jung C, Kirov M, Kobari S, Lakbar I, Lipman J, Liu V, Liu X, Lobo SM, Magatti D, Martin GS, Metnitz B, Metnitz P, Myatra SN, Oczkowski S, Paiva JA, Paruk F, Pekkarinen PT, Piquilloud L, Polkki A, Prescott HC, Blaser AR, Rezende E, Robba C, Rochwerg B, Ruckly S, Samei R, Schenck EJ, Secombe P, Sendagire C, Siaw-Frimpong M, Simpkin AJ, Soares M, Summers C, Szczeklik W, Takala J, Tanaka S, Tricella G, Vincent JL, Wendon J, Zampieri FG, Rhodes A, Moreno R. Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. JAMA. 2025 Dec 16;334(23):2090-2103. doi: 10.1001/jama.2025.20516. PubMed 41159833 ↗
  • Prescott HC, Antonelli M, Alhazzani W, Moller MH, Alshamsi F, Azevedo LCP, Belley-Cote E, De Waele J, Derde L, Dionne JC, Evans L, Gershengorn HB, Hodgson CL, Honarmand K, Kesecioglu J, McIntyre L, Mer M, Nunnally ME, Oczkowski SJW, Rochwerg B, Akinola OO, Akuamoah-Boateng KA, Alberto L, Angus DC, Arabi YM, Azoulay E, Cecconi M, Convocar PF, De Pascale G, Doi K, Du B, Egi M, Elie-Turenne MC, Ferrer R, Fox-Robichaud A, French C, Freund Y, Gong MN, Hale CP, Hammond NE, Hashmi M, Heunks L, Iwashyna TJ, Jacob ST, Klompas M, Kwizera A, Leeies M, Lejnieks JD, Levy MM, Machado FR, Maia MO, Masur H, Maves RC, McGloughlin S, McPeake J, Mohr NM, Myatra SN, Ostermann M, Peake SL, Pletz MW, Roberts JA, Rosa RG, Sawyer RG, Schorr CA, Simpson SQ, Weng L, Wiersinga WJ, Rhodes A, Coopersmith CM. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026 Apr 1;54(4):725-812. doi: 10.1097/CCM.0000000000007075. Epub 2026 Mar 23. No abstract available. PubMed 41869847 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available because consent for public data sharing was not obtained in this single-center study. Aggregate results will be published in peer-reviewed journals and reported on ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 23 months is close to that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2028
CompletionEst.
Nov 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950111
Lead sponsor
The 108 Military Central Hospital
Collaborators
Vietnam Military Medical University, Thanh Phuong Co., Ltd
Responsible party
Bui Viet Hoan (PhD Candidate in Anesthesiology and Critical Care, The 108 Military Central Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Bui Viet Hoan, MD
Contact
bvhoan108@gmail.com
+84 987 649 061
Bui Viet Hoan, MD
principal investigator · The 108 Military Central Hospital
Pham Dang Hai, MD, PhD
study chair · The 108 Military Central Hospital
Le Xuan Duong, MD, PhD
study chair · The 108 Military Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion